Kymera Therapeutics, Inc.KYMRNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank68
5Y CAGR-14.7%
Year-over-Year Change
Year-over-year research & development expense growth
5Y CAGR
-14.7%/yr
Long-term compound
Percentile
P68
Within normal range
vs 5Y Ago
0.5x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 13.18% |
| Q3 2025 | -5.48% |
| Q2 2025 | -2.33% |
| Q1 2025 | 11.75% |
| Q4 2024 | 18.88% |
| Q3 2024 | 2.04% |
| Q2 2024 | 21.27% |
| Q1 2024 | -7.84% |
| Q4 2023 | 10.09% |
| Q3 2023 | 5.13% |
| Q2 2023 | 8.38% |
| Q1 2023 | -2.10% |
| Q4 2022 | -1.70% |
| Q3 2022 | 6.26% |
| Q2 2022 | 14.88% |
| Q1 2022 | -4.23% |
| Q4 2021 | -2.03% |
| Q3 2021 | 8.76% |
| Q2 2021 | 35.66% |
| Q1 2021 | 27.31% |
| Q4 2020 | 29.24% |
| Q3 2020 | 14.18% |
| Q2 2020 | 14.06% |
| Q1 2020 | 9.29% |
| Q4 2019 | -1.98% |
| Q3 2019 | 0.00% |